Pacific Biosciences (PACB) 8.21 $PACB
Pacific Biosciences of California Shares Down 27.8% Since SmarTrend's Sell Call (PACB)
Comtex SmarTrend(R) - Thu Mar 24, 12:40AM CDT
SmarTrend identified a Downtrend for Pacific Biosciences of California (NASDAQ
ACB) on January 28th, 2016 at $10.73. In approximately 2 months, Pacific Biosciences of California has returned 27.83% as of today's recent price of $7.74.
PACB: 8.21 (+0.47)
Look for Shares of Pacific Biosciences of California to Potentially Pullback after Yesterday's 1.44% Rise
Comtex SmarTrend(R) - Mon Mar 21, 4:54PM CDT
Pacific Biosciences of California (NASDAQ ACB) traded in a range yesterday that spanned from a low of $8.27 to a high of $8.73. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $8.66 on volume of 505,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PACB: 8.21 (+0.47)
Is This the Biggest Threat Yet to Illumina?
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 18, 4:41PM CDT
IMAGE SOURCE: ILLUMINA INC. Illumina has held go-to status as the dominant maker of gene-sequencing devices for years, but a new, next-generation gene-sequencing machine made by Pacific Biosciences aims to change that. Can Illumina fend off...
PACB: 8.21 (+0.47), ILMN: 155.34 (+2.80)
Is It Time to Buy Illumina Inc. Stock?
Keith Speights, The Motley Fool - Motley Fool - Mon Mar 14, 10:39AM CDT
Image Source: Illumina It's been a rough winter for Illumina shareholders. The genomic sequencing company's stock plunged nearly 30% by early February before regaining some of those losses. However, Illumina's shares are still way down...
PACB: 8.21 (+0.47), TMO: 139.02 (+0.20), ILMN: 155.34 (+2.80)
Why Pacific Biosciences Lost 18.6% of Its Value Last Month
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 12, 9:21AM CST
SOURCE: PACIFIC BIOSCIENCES. What: Following a forecast for a slow launch schedule for its next generation gene sequencer and the admission that it will need more cash, shares in Pacific Biosciences tumbled 18.6% last month, according to ...
PACB: 8.21 (+0.47), ILMN: 155.34 (+2.80)
Shares of PACB Down 19.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 03, 3:25PM CST
SmarTrend identified a Downtrend for Pacific Biosciences of California (NASDAQ ACB) on January 28th, 2016 at $10.73. In approximately 1 month, Pacific Biosciences of California has returned 19.35% as of today's recent price of $8.65.
PACB: 8.21 (+0.47)
Biotechnology Equities Technical Commentary -- Relypsa, PDL BioPharma, Pacific Biosciences of California, and Clovis Oncology
ACCESSWIRE - Tue Feb 09, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / Park Lane Advisor has initiated coverage on the following equities: Relypsa Inc. (NASDAQ: RLYP), PDL BioPharma Inc. (NASDAQ: PDLI), Pacific Biosciences of California Inc. (NASDAQ: PACB), and Clovis Oncology Inc. (NASDAQ: CLVS). Free note on Relypsa can be accessed at http://www.parklaneadvisor.com/ On Monday, February 08, 2016, the NASDAQ Composite ended at 4,283.75, down 1.82%, the Dow Jones Industrial Average declined 1.10%, to finish the day at 16,027.05, and the S&P 500 closed at 1,853.44, down 1.42%. Register for your complimentary reports at the links given below.
PACB: 8.21 (+0.47), CLVS: 19.03 (+0.41), RLYP: 13.24 (+0.32), PDLI: 3.11 (-0.08)
Why Shares of Pacific Biosciences of California Plunged 23% Today
Travis Hoium, The Motley Fool - Motley Fool - Thu Feb 04, 11:21AM CST
What: Shares of gene sequencing company Pacific Biosciences of California plunged 23% in midday trading on Thursday after the company reported earnings that underwhelmed investors. So what: Fourth-quarter revenue surged 115% to $36.3 million...
PACB: 8.21 (+0.47)
Pacific Biosciences of California Doubles Revenue in Q4
Travis Hoium, The Motley Fool - Motley Fool - Thu Feb 04, 11:12AM CST
The sequencing business continues to hold a lot of promise for Pacific Biosciences of California , but it will take a little longer to start seeing its full potential. The company reported fourth-quarter 2015 earnings after the market closed on...
PACB: 8.21 (+0.47)
Pacific Biosciences (PACB) Stock Plunges on Q4 Loss
at The Street - Thu Feb 04, 10:04AM CST
Pacific Biosciences (PACB) stock is sinking in mid-morning trading on Thursday after the company reported a loss during the 2015 fourth quarter.
PACB: 8.21 (+0.47)
Pacific Biosciences Posts Q4 Loss, Stock Down on FY16 View
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 9:20AM CST
Pacific Biosciences of California Inc. (PACB) reported loss of 2 cents per share in the fourth quarter of 2015, in line with the Zacks Consensus Estimate.
ABMD: 90.60 (-0.94), PACB: 8.21 (+0.47), EXAC: 18.52 (+0.16), CRY: 10.40 (-0.07)
Downgrade Alert for Pacific Biosciences of California (PACB)
Comtex SmarTrend(R) - Thu Feb 04, 7:16AM CST
Pacific Biosciences of California (NASDAQ ACB) was downgraded from Overweight to Neutral at Piper Jaffray today. The stock closed yesterday at $12.37 on volume of 3.9 million shares, above average daily volume of 2.6 million. Pacific Biosciences of California share prices have moved between a 52-week high of $14.00 and a 52-week low of $3.58 and closed yesterday at 246% above that low price at $12.37 per share. Over the last five market days, the 200-day moving average (MA) has gone up 1.1% while the 50-day MA has advanced 1.5%.
PACB: 8.21 (+0.47)
Pacific Biosciences' Q4 2015 net loss lowers to USD1.4m
M2 - Thu Feb 04, 4:07AM CST
Genetic analysis company Pacific Biosciences of California (NasdaqGS ACB) stated on Wednesday its net loss of USD1.4m its fourth quarter ended 31 December 2015.
PACB: 8.21 (+0.47)
Pacific Biosciences reports 4Q loss
Automated Insights - Wed Feb 03, 3:47PM CST
MENLO PARK, Calif. (AP) _ Pacific Biosciences of California Inc. (PACB) on Wednesday reported a loss of $1.4 million in its fourth quarter.
PACB: 8.21 (+0.47)
Pacific Biosciences Announces Fourth Quarter 2015 Financial Results
GlobeNewswire - Wed Feb 03, 3:00PM CST
Pacific Biosciences of California, Inc. (NASDAQ ACB) today announced financial results for its fourth quarter ended December 31, 2015.
PACB: 8.21 (+0.47)
Pacific Biosciences (PACB) Jumps: Stock Moves Up 24.3%
Zacks Equity Research - Zacks Investment Research - Wed Feb 03, 7:15AM CST
Pacific Biosciences of California, Inc. (PACB) shares rose above 24% in the last trading session.
PACB: 8.21 (+0.47)
Why Pacific Biosciences of California's Shares Popped 25% Today
Travis Hoium, The Motley Fool - Motley Fool - Tue Feb 02, 3:14PM CST
What: Shares of Pacific Biosciences of California surged as much as 37% in late trading today after rumors emerged of a potential buyout. With just minutes left in the trading day, shares had settled to a 25% gain. So what: Reuters is...
PACB: 8.21 (+0.47)
Pacific Biosciences of California Shares Down 27.8% Since SmarTrend's Sell Call (PACB)
Comtex SmarTrend(R) - Thu Mar 24, 12:40AM CDT
SmarTrend identified a Downtrend for Pacific Biosciences of California (NASDAQ
ACB) on January 28th, 2016 at $10.73. In approximately 2 months, Pacific Biosciences of California has returned 27.83% as of today's recent price of $7.74. PACB: 8.21 (+0.47)
Look for Shares of Pacific Biosciences of California to Potentially Pullback after Yesterday's 1.44% Rise
Comtex SmarTrend(R) - Mon Mar 21, 4:54PM CDT
Pacific Biosciences of California (NASDAQ
ACB) traded in a range yesterday that spanned from a low of $8.27 to a high of $8.73. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $8.66 on volume of 505,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PACB: 8.21 (+0.47)
Is This the Biggest Threat Yet to Illumina?
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 18, 4:41PM CDT
IMAGE SOURCE: ILLUMINA INC. Illumina has held go-to status as the dominant maker of gene-sequencing devices for years, but a new, next-generation gene-sequencing machine made by Pacific Biosciences aims to change that. Can Illumina fend off...
PACB: 8.21 (+0.47), ILMN: 155.34 (+2.80)
Is It Time to Buy Illumina Inc. Stock?
Keith Speights, The Motley Fool - Motley Fool - Mon Mar 14, 10:39AM CDT
Image Source: Illumina It's been a rough winter for Illumina shareholders. The genomic sequencing company's stock plunged nearly 30% by early February before regaining some of those losses. However, Illumina's shares are still way down...
PACB: 8.21 (+0.47), TMO: 139.02 (+0.20), ILMN: 155.34 (+2.80)
Why Pacific Biosciences Lost 18.6% of Its Value Last Month
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 12, 9:21AM CST
SOURCE: PACIFIC BIOSCIENCES. What: Following a forecast for a slow launch schedule for its next generation gene sequencer and the admission that it will need more cash, shares in Pacific Biosciences tumbled 18.6% last month, according to ...
PACB: 8.21 (+0.47), ILMN: 155.34 (+2.80)
Shares of PACB Down 19.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 03, 3:25PM CST
SmarTrend identified a Downtrend for Pacific Biosciences of California (NASDAQ
ACB) on January 28th, 2016 at $10.73. In approximately 1 month, Pacific Biosciences of California has returned 19.35% as of today's recent price of $8.65. PACB: 8.21 (+0.47)
Biotechnology Equities Technical Commentary -- Relypsa, PDL BioPharma, Pacific Biosciences of California, and Clovis Oncology
ACCESSWIRE - Tue Feb 09, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / Park Lane Advisor has initiated coverage on the following equities: Relypsa Inc. (NASDAQ: RLYP), PDL BioPharma Inc. (NASDAQ: PDLI), Pacific Biosciences of California Inc. (NASDAQ: PACB), and Clovis Oncology Inc. (NASDAQ: CLVS). Free note on Relypsa can be accessed at http://www.parklaneadvisor.com/ On Monday, February 08, 2016, the NASDAQ Composite ended at 4,283.75, down 1.82%, the Dow Jones Industrial Average declined 1.10%, to finish the day at 16,027.05, and the S&P 500 closed at 1,853.44, down 1.42%. Register for your complimentary reports at the links given below.
PACB: 8.21 (+0.47), CLVS: 19.03 (+0.41), RLYP: 13.24 (+0.32), PDLI: 3.11 (-0.08)
Why Shares of Pacific Biosciences of California Plunged 23% Today
Travis Hoium, The Motley Fool - Motley Fool - Thu Feb 04, 11:21AM CST
What: Shares of gene sequencing company Pacific Biosciences of California plunged 23% in midday trading on Thursday after the company reported earnings that underwhelmed investors. So what: Fourth-quarter revenue surged 115% to $36.3 million...
PACB: 8.21 (+0.47)
Pacific Biosciences of California Doubles Revenue in Q4
Travis Hoium, The Motley Fool - Motley Fool - Thu Feb 04, 11:12AM CST
The sequencing business continues to hold a lot of promise for Pacific Biosciences of California , but it will take a little longer to start seeing its full potential. The company reported fourth-quarter 2015 earnings after the market closed on...
PACB: 8.21 (+0.47)
Pacific Biosciences (PACB) Stock Plunges on Q4 Loss
at The Street - Thu Feb 04, 10:04AM CST
Pacific Biosciences (PACB) stock is sinking in mid-morning trading on Thursday after the company reported a loss during the 2015 fourth quarter.
PACB: 8.21 (+0.47)
Pacific Biosciences Posts Q4 Loss, Stock Down on FY16 View
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 9:20AM CST
Pacific Biosciences of California Inc. (PACB) reported loss of 2 cents per share in the fourth quarter of 2015, in line with the Zacks Consensus Estimate.
ABMD: 90.60 (-0.94), PACB: 8.21 (+0.47), EXAC: 18.52 (+0.16), CRY: 10.40 (-0.07)
Downgrade Alert for Pacific Biosciences of California (PACB)
Comtex SmarTrend(R) - Thu Feb 04, 7:16AM CST
Pacific Biosciences of California (NASDAQ
ACB) was downgraded from Overweight to Neutral at Piper Jaffray today. The stock closed yesterday at $12.37 on volume of 3.9 million shares, above average daily volume of 2.6 million. Pacific Biosciences of California share prices have moved between a 52-week high of $14.00 and a 52-week low of $3.58 and closed yesterday at 246% above that low price at $12.37 per share. Over the last five market days, the 200-day moving average (MA) has gone up 1.1% while the 50-day MA has advanced 1.5%. PACB: 8.21 (+0.47)
Pacific Biosciences' Q4 2015 net loss lowers to USD1.4m
M2 - Thu Feb 04, 4:07AM CST
Genetic analysis company Pacific Biosciences of California (NasdaqGS
ACB) stated on Wednesday its net loss of USD1.4m its fourth quarter ended 31 December 2015. PACB: 8.21 (+0.47)
Pacific Biosciences reports 4Q loss
Automated Insights - Wed Feb 03, 3:47PM CST
MENLO PARK, Calif. (AP) _ Pacific Biosciences of California Inc. (PACB) on Wednesday reported a loss of $1.4 million in its fourth quarter.
PACB: 8.21 (+0.47)
Pacific Biosciences Announces Fourth Quarter 2015 Financial Results
GlobeNewswire - Wed Feb 03, 3:00PM CST
Pacific Biosciences of California, Inc. (NASDAQ
ACB) today announced financial results for its fourth quarter ended December 31, 2015. PACB: 8.21 (+0.47)
Pacific Biosciences (PACB) Jumps: Stock Moves Up 24.3%
Zacks Equity Research - Zacks Investment Research - Wed Feb 03, 7:15AM CST
Pacific Biosciences of California, Inc. (PACB) shares rose above 24% in the last trading session.
PACB: 8.21 (+0.47)
Why Pacific Biosciences of California's Shares Popped 25% Today
Travis Hoium, The Motley Fool - Motley Fool - Tue Feb 02, 3:14PM CST
What: Shares of Pacific Biosciences of California surged as much as 37% in late trading today after rumors emerged of a potential buyout. With just minutes left in the trading day, shares had settled to a 25% gain. So what: Reuters is...
PACB: 8.21 (+0.47)
